Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quest launches "most comprehensive" colorectal cancer gene test

This article was originally published in Clinica

Executive Summary

Quest Diagnostics has launched its EGFR Pathway test for mutations that affect colorectal cancer patients' response to EGFR-inhibiting drugs, such as Amgen's Vectibix. Quest's product detects mutations in the KRAS, NRAS and BRAF genes, whereas similar tests only identify KRAS mutations. These are found in around 40% of colorectal cancer patients, and are associated with a poor response to EGFR inhibitors. However, these drugs are not effective in all patients with normal KRAS – 5% and 8% of patients with normal KRAS genes are thought to carry NRAS and BRAF mutations, respectively, which are also linked to a poor response. Madison, New Jersey-based Quest claims that EGFR Pathway provides the most comprehensive data available on KRAS, NRAS and BRAF mutations from a single test.

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts